Supplementary figure 1. Concentration-effect curve for dupilumab level and ΔEASI at 24 weeks in patients with a moderate-to-severe baseline EASI (≥6.0).

Concentration-effect curve for patients with a moderate-to-severe baseline EASI (≥6.0) showing the dupilumab serum level in μg/mL at 24 weeks on the x-axis and correlating ΔEASI at 24 weeks (versus baseline) on the y-axis. All patients were sorted from low to high drug concentration, with each dot representing the mean concentration with SDs and correlating ΔEASI for 10 patients (last group 9 patients).